Evidence map›Paper›PMID 41987317›Full record

ArticleJournal of magnetic resonance imaging : JMRI2026

Comparison of Diagnostic Performance Between Standard Susceptibility Map-Weighted Imaging and Susceptibility Map-Weighted Imaging Reconstructed From Clinical SWI and Neuromelanin MRI in Early Parkinson's Disease.

Seon Lee, Yongsik Sim, Jinyoung Youn, Eung Yeop Kim, Seung Hwan Moon, Sun-Young Baek, Beomseok Sohn

Abstract readComparative Study
In one paragraph

Article in Journal of magnetic resonance imaging : JMRI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Seon LeeDepartment of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0002-7451-1706
Yongsik SimDepartment of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0003-2711-2793
Jinyoung YounDepartment of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0003-3350-5032
Eung Yeop KimDepartment of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0002-9579-4098
Seung Hwan MoonDepartment of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0003-4302-1920
Sun-Young BaekDepartment of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0001-6519-7770
Beomseok SohnDepartment of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0002-6765-8056

Funding

Ministry of Health & Welfare RS-2023-00266288National Research Foundation of Korea (NRF) RS-2023-00237618National Research Foundation of Korea (NRF) RS-2026-25468417
6 · The paper itself

Abstract

backgroundSusceptibility map-weighted imaging (SMwI) provides high accuracy for early Parkinson's disease (ePD) by enhancing nigral hyperintensity. However, standard SMwI requires dedicated acquisition; reconstruction from routinely acquired sequences may offer a practical alternative. PURPOSE: To compare the diagnostic performance of standard SMwI with SWI- and neuromelanin (NM)-driven SMwI for differentiating ePD from disease controls (DC). STUDY TYPE: Retrospective. SUBJECTS: One hundred and eighty-seven drug-naïve ePD (age: 67.5 ± 9.4 years, 102 male) and 43 DC (age: 67.1 ± 9.2 years, 12 male). FIELD STRENGTH/SEQUENCE: 3 T, multi-echo gradient-echo (GRE) for standard SMwI; GRE-based NM imaging: multi-echo GRE for SWI. ASSESSMENT: Nigral hyperintensity was assessed by three neuroradiologists (4-, 2-, and 1-year experience). Diagnostic performance was evaluated using clinical diagnosis for all subjects and PET for 106 subjects (98 ePD, 8 DC). PET-based assessment included side-based analyses accounting for PET laterality and patient-based analyses regardless of direction. STATISTICAL TESTS: Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy and area under the curve (AUC) were assessed using clinical diagnosis as reference; sensitivity, specificity, and accuracy using PET. Significance was set at p < 0.05.

resultsUsing clinical diagnosis as reference, standard SMwI showed highest diagnostic performance (sensitivity 0.856; specificity 1.000; PPV 1.000; AUC 0.928). SWI-driven SMwI maintained similar sensitivity (p = 0.355) but showed significantly reduced specificity, PPV, accuracy, AUC. In the PET subgroup, side- and patient-based analyses showed no differences in sensitivity (p = 0.261, p = 0.670), specificity (p = 1.000, p = 1.000) and accuracy (p = 0.268, p = 0.695) between standard and SWI-driven SMwI. DATA

conclusionSWI-driven SMwI approached the diagnostic performance of standard SMwI with PET reference but showed inferior performance with clinical diagnosis, suggesting a fallback option when dedicated SMwI is unavailable. EVIDENCE LEVEL: 3. TECHNICAL EFFICACY: Stage 1.

Indexed as

Image Processing, Computer-AssistedMagnetic Resonance ImagingMelaninsParkinson DiseaseAgedBrainFemaleHumansImage Interpretation, Computer-AssistedMaleMiddle AgedPositron-Emission TomographyReproducibility of ResultsRetrospective StudiesSensitivity and SpecificityMelaninsneuromelaninearly Parkinson's diseaseneuromelanin imagingreconstructionsusceptibility map‐weighted imagingsusceptibility‐weighted image

Identifiers

PMID41987317
PMCPMC13356449

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.